Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07282613 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Not yet
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT07282613 is a Phase 3 study that has not yet begun recruiting, run by Novo Nordisk A/S. The registered enrollment target is 80 participants.
The verdict
NCT07282613, a Phase 3 study, has not yet begun recruiting, sponsored by Novo Nordisk A/S.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The study will last for about 1 year and 3 months.
Interventions
- DRUG CagriSema (Cagrilintide B and Semaglutide I)
- DRUG Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-08-04 |
| Est. Completion | 2030-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07282613
The ClinicalTrials.gov registry entry for NCT07282613 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CagriSema (Cagrilintide B and Semaglutide I) is the first listed.
NCT07282613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07282613 about?
NCT07282613 is a clinical study titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes". The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part...
What is the current status of trial NCT07282613?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2026-08-04. Estimated completion is 2030-03-30.
What interventions are being tested in trial NCT07282613?
The interventions under investigation include: CagriSema (Cagrilintide B and Semaglutide I) (DRUG), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) (DRUG).
Who is sponsoring clinical trial NCT07282613?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.